ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer

Hong, Xin; Michalski, Christoph; Kong, Bo; Zhang, Wei Wei; Raggi, Matthias C.; Sauliunaite, Danguole; Oliveira, Tiago De; Friess, Helmut; Kleeff, Jörg

doi:10.1002/jso.21538

Cited by 40 publications

(49 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hong and colleagues recently described a prognostic effect of ALCAM in PNET, but did not substantiate this with results or details in their manuscript [21]. Nevertheless, they performed in vitro ALCAM RNAi experiments in their study with a PNET cell line (BON), and observed a significant reduction in the proliferative activity of the tumor cells, which is in clear contrast to our immunohistochemical findings.…”

Section: Discussioncontrasting

confidence: 87%

“…This ambiguity is very clear in the oppositional effect of ALCAM in neuroendocrine tumors and adenocarcinoma of the pancreas. A high expression of ALCAM is reported to be associated with a poor prognosis for patients with pancreatic adenocarcinoma [11,21]. As a consequence, it is highly unlikely that ALCAM functions as a receptor for metastatic deor attachment in the same primary or metastatic host tissue, but it might play a regulatory role in this process.…”

Section: Discussionmentioning

confidence: 99%

“…ALCAM is a highly conserved 110 kDa multidomain transmembrane type 1 glycoprotein of the immunoglobulin superfamily and mediates homotypic and heterotypic interactions between cells [12]. The extracellular domain of ALCAM (s-ALCAM) is shed by metalloproteases (for example ADAM 17) and can be detected in the serum of cancer patients, serving as a diagnostic biomarker [17][18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

Tachezy

Zander

Marx

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

Tachezy

Zander

Marx

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

“…CD166 is involved in hematopoiesis (19,20), neurite extension (21), osteogenesis (22), and embryonic implantation in the uterus (23). The level of CD166 expression correlates with the aggregation and metastatic potential of a few human tumors (24), including melanoma (25,26) and prostate (27,28), ovarian (29), breast (30 -32), colorectal (33,34), esophageal (35), and pancreatic cancer (36,37). Furthermore, AL-CAM was also identified in medium conditioned by breast cancer cells and may be a potential serum breast cancer biomarker (38,39).…”

Section: Discussionmentioning

confidence: 99%

Plasma Membrane Proteomics of Tumor Spheres Identify CD166 as a Novel Marker for Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma

Yan

Yang

Wang

et al. 2013

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Patients with advanced head and neck squamous cell carcinoma (HNSCC) have a poor prognosis with the currently available therapy, and tumor recurrence is frequently observed. The discovery of specific membraneassociated cancer stem cell (CSC) markers is crucial for the development of novel therapeutic strategies to target these CSCs. To address this issue, we established sphere cultures to enrich CSCs and used them for plasma membrane proteomics to identify specific membrane signatures of the HNSCC spheres. Of a dataset that included a total of 376 identified proteins, 200 were bona fide membrane proteins. Among them, 123 proteins were at least 1.5-fold up-or down-regulated in the spheres relative to the adherent cultures. These proteins included cell adhesion molecules, receptors, and transporter proteins. Some of them play key roles in wnt, integrin, and TGF␤ signaling pathways. When we compared our dataset with two published hESC membrane protein signatures, we found 18 proteins common to all three of the databases. CD166 and CD44 were two such proteins. Interestingly, the expression of CD166, rather than that of the wellestablished HNSCC CSC marker CD44, was significantly related to the malignant behavior of HNSCC. Relative to Head and neck squamous cell carcinoma (HNSCC)1 is the sixth most common cancer worldwide. Despite ongoing improvement in traditional treatments, the long-term survival rate of patients with HNSCC has not significantly improved over the past several decades. More than 60% of patients with advanced tumors or localized lymph node metastases die within five years of their diagnosis (1). Tumor recurrence and resistance to therapy are the major causes of death. Recently, newly recognized cancer stem cells (CSCs) or tumor-initiating cells have been associated in a cause-andeffect manner with tumor recurrence and resistance to therapy. The concept of CSCs was established because of the heterogeneous nature of cancer and suggests that CSCs are a subpopulation of cancer cells with stem-cell-like traits and the source of all cells in the cancer. Conventional cancer therapies such as chemotherapy and radiotherapy may destroy only those cells that form the bulk of the tumor, leaving the CSCs intact and able to give rise to tumor recurrence. Based on this theory, researchers are searching for therapies that would destroy CSCs in the hope of finally curing cancer (2). In order to develop strategies that target CSCs, experimental assays are required to determine how to distinguish CSCs from their progeny. Different methods have been used to isolate CSCs from a range of hematopoietic and solid tumors, and some CSC-specific cell surface markers have been found. These markers are primarily selected from the From the ‡Shanghai Key

show abstract

“…Few studies report altered serum levels in pancreatic cancer [21] and ovarian cancer [22] but make no statement about its prognostic value. To our knowledge, we are the first to note that high sALCAM levels are a predictor of shorter DFS in breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Detection of Activated Leukocyte Cell Adhesion Molecule in the Serum of Breast Cancer Patients and Implications for Prognosis

Witzel¹,

Schröder²,

Müller³

et al. 2012

Oncology

View full text Add to dashboard Cite

Objective: Conflicting results have been reported about activated leukocyte cell adhesion molecule (ALCAM) expression in breast cancer and its prognostic value. Little is known about the role of ALCAM levels in the serum of breast cancer patients. Methods: We analyzed soluble ALCAM (sALCAM) levels in the serum of 157 primary breast cancer patients and 48 healthy women by ELISA. In addition, we determined ALCAM protein expression by Western blot analysis (n = 120) and mRNA expression by cDNA microarray analysis (n = 115) in the tumor tissue of corresponding patients. Results: sALCAM levels differed between patients and healthy controls (median 24.2 vs. 18.9 ng/ml, p < 0.001). We observed no correlation between serum levels and protein or mRNA expression in corresponding tumors (r < 0.1, p = n.s.). sALCAM levels were not correlated with histological type, grading, tumor stage, or patient age, but elevated sALCAM levels were associated with shorter disease-free survival (HR = 1.97, 95% CI 1.01–3.2, p = 0.043). Conclusions: Our results indicate that sALCAM can be detected in the serum of patients with primary breast cancer. Elevated serum levels might indicate more aggressive tumor behavior as they might be an independent factor for a worse prognosis in breast cancer patients.

show abstract

ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer

Abstract: We propose ALCAM as a novel serum biomarker in human pancreatic tumors which is associated with cell adhesion, growth and chemoresistance.

Cited by 40 publications

References 34 publications

ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

Plasma Membrane Proteomics of Tumor Spheres Identify CD166 as a Novel Marker for Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma

Detection of Activated Leukocyte Cell Adhesion Molecule in the Serum of Breast Cancer Patients and Implications for Prognosis

Contact Info

Product

Resources

About